Mineralys Therapeutics (MLYS) Set to Announce Quarterly Earnings on Thursday

Mineralys Therapeutics (NASDAQ:MLYS) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.68) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.61) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.24. On average, analysts expect Mineralys Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Mineralys Therapeutics Stock Up 3.3 %

MLYS traded up $0.46 on Tuesday, reaching $14.21. The stock had a trading volume of 165,514 shares, compared to its average volume of 159,799. The business’s 50-day moving average price is $12.98 and its two-hundred day moving average price is $10.57. Mineralys Therapeutics has a 12-month low of $5.85 and a 12-month high of $17.70.

Insider Transactions at Mineralys Therapeutics

In other news, major shareholder Samsara Biocapital Gp, Llc acquired 555,555 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were bought at an average cost of $13.50 per share, for a total transaction of $7,499,992.50. Following the acquisition, the insider now owns 5,074,916 shares in the company, valued at approximately $68,511,366. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 33.24% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on MLYS. Lifesci Capital restated an “outperform” rating on shares of Mineralys Therapeutics in a research note on Tuesday, March 26th. The Goldman Sachs Group began coverage on Mineralys Therapeutics in a research note on Tuesday, April 2nd. They set a “buy” rating and a $30.00 target price for the company.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.